drugset / Trial / NCT00098397

FR901228 in Treating Patients With Metastatic Breast Cancer

NCT00098397

Phase 2 Completed 37 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well FR901228 works in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Timeline

Start
2005-02
Primary completion
2005-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide Intravenous

Indications